News

Kara Therapeutics to Present at Canaccord Genuity 42nd Annual Development Conference

Kara Therapeutics, Inc.

STAMFORD, Conn., August 03, 2022 (Globe Newswire) — CARA Therapeutics, Inc. (Nasdaq: CARA), a commercial-scale biopharmaceutical company pioneering a new treatment paradigm to improve the lives of patients with pruritus, announced today. That Christopher Posner, President and Chief Executive Officer, will attend the Canaccord Genuity 42nd Annual Development Conference on Wednesday, August 10, 2022 at 9:30 a.m. ET.

The webcast of the presentation can be accessed under “Events and Presentations” in the News and Investors section of the Company’s website www.CaraTherapeutics.com. An archived webcast recording will be available on the CARA website for approximately 30 days.

About Kara Therapeutics

Kara Therapeutics is a commercial scale biopharmaceutical company pioneering a new treatment paradigm to improve the lives of patients suffering from pruritus. The company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate to severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The company is developing an oral formulation of difelikefalin and has started a phase 3 program for the treatment of pruritus in patients with non-dialysis-dependent advanced chronic kidney disease and atopic dermatitis. The company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral deflakephalin for the treatment of moderate to severe pruritus in patients with Notalgia paresthetica. A phase 2 proof-of-concept trial is underway in primary cholangitis patients with moderate to severe pruritus. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn, and Instagram.

media Contact:
Annie Spinetta
6 degrees
973-768-2170
[email protected]

Investor Contact:
Iris Francesconi, Ph.D.
Kara Therapeutics
203-406-3700
[email protected]

Source